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Objective: To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI).
Materials and Methods: We prospectively enrolled 168 subjects affected by LUTS due to 
bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate 
cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with 
histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, 
randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control 
group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of 
BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II) 
for 3 months or to control group (group IIc). After 6 months first group underwent 24 
cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent 
two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation pa-
rameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68).
Results: At follow-up there were statistical significant reductions of extension and gra-
ding of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I com-
pared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not 
statistical significant. A statistically significant reduction in the density of CD20, CD3, 
CD68, CD8 was demonstrated in group II in respect to control IIc.
Conclusions: Serenoa repens+Selenium+Lycopene may have an anti-inflammatory acti-
vity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients.
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a 
common cause of bothersome lower urinary tract 
symptoms in man, representing a growing entity 
in terms of healthcare costs and morbidity.
 Approximately 50% of men aged between 
50 and 60 years, 60% of men aged between 60 
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and 70 years, and up to 90% of men aged > 80 
years have some degree of benign prostatic enlar-
gement (BPE) (1).
Medical therapies can provide adequate al-
leviation of BPE symptoms (LUTS): The two prima-
ry classes of oral medications that are prescribed 
for the treatment of symptoms are alpha-blockers 
and 5-alpha-reductase inhibitors (5ARIs). Despi-
te medical therapy improves LUTS, some adverse 
events (ejaculatory dysfunction, loss of libido, erec-
tile dysfunction) are caused by the treatment, wor-
sening an already compromised sexual function (2).
The aetiology of BPH is still far from being 
fully understood but multiple partially overlapping 
and complementary theories have been proposed 
(3). There are some evidences that prostatic inflam-
mation could be a key component in BPE and BPH 
progression.
Two of the major clinical studies on BPH 
(MTOPS and Reduce study) recently demonstrated 
the link between histological prostatic inflamma-
tion and prostate enlargement or symptoms scores 
(4,5). Numerous major key players in chronic in-
flammation have been studied in BPH: varieties of 
growth factors and cytokines have been shown to 
be involved both in the inflammatory process and 
in the epithelial/stromal prostatic cells interactions 
(6). These mediators are released in the prostatic 
gland by inflammatory cells that can be found on 
most of the surgery-derived BPH specimens (7).
The inflammatory cells may trigger a so-
phisticated and well-orchestrated inflammatory 
cascade, resulting in excessive oxidative stress, ac-
tivation of the transcription factor nuclear factor-
-kappa B (NF-κB), production of several cytokines 
and overexpression of inducible-cyclooxygenase 
(COX-2), inducible-nitric-oxide-synthase (iNOS) 
and 5-lipoxygenase (5-LOX), leading, in turn, to 
the release of prostaglandins, nitrates, and leu-
kotrienes. Furthermore, inflammatory cells pro-
duce growth factors, such as vascular endothelial 
growth factor (VEGF) and transforming growth 
factor-β (TGF-β), which may support fibromuscu-
lar growth in BPH (8).
Plant extracts have been used in the me-
dical management of BPH-induced LUTS with the 
aim to relieve symptoms without adverse events 
related to treatment (9).
Serenoa Repens (SeR), derived from the 
berries of the saw palmetto tree, is the most popu-
lar naturally derived medication for BPH (10). Se-
veral mechanisms of action have been proposed to 
explain its therapeutic efficacy, including inhibi-
tion of 5α-reductase and dihydrotestosterone bin-
ding to androgen receptors, a weak α1-adrenergic 
receptor antagonism, inhibition of growth factors-
-induced prostate cell proliferation and inhibition 
of COX-2 and 5-LOX (11).
Besides SeR, both lycopene (LY), a dieta-
ry carotenoid synthesized by plants, fruits, and 
microorganisms with a strong antioxidant activi-
ty, and selenium (Se), an essential trace element 
mainly functioning through seleno-proteins and 
able to promote an optimal antioxidant/oxidant 
balance, have been shown to exert beneficial 
effects in BPH (12-16).
The aim of this study is to evaluate the effi-
cacy of Profluss® ( SeR-Se-LY) in reducing chro-
nic inflammation in patient with benign prostatic 
hyperplasia and/or PIN/ASAP.
MATERIALS AND METHODS
Study design, patients selection criteria and 
allocation
The “Flogosis And Profluss in Prostatic and 
Genital Disease” (FLOG) study was a multicentre stu-
dy involving 9 urological Italian centres between Ja-
nuary 2009 and December 2010 that analysed pros-
pectively collected data of two category of patients 
affected by BPH and/or PIN/ASAP. The inclusion 
criteria for the first group were: presence of LUTS 
due to bladder outlet obstruction (BOO) secondary 
to clinical BPH, assessed by urodynamic and pres-
sure flow evaluation, PSA > 4ng/mL and/or DRE 
abnormality and/or abnormal findings on transrec-
tal ultrasound, 12 cores prostatic biopsy performed 
for suspected prostate cancer with two more cores 
collected from the left and right lobes (for chronic 
inflammation evaluation), histological diagnosis of 
prostatic chronic inflammation associated with BPH 
and high grade PIN and/or ASAP. Exclusion criteria 
were: treatment with NSAIDs or corticosteroids in 
the previous 6 months, urinary infection, treatment 
with finasteride or dutasteride, phytotherapy in the 
previous 6 months; diagnosis of prostatic cancer 
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(PCa). Fourty patients were excluded after PCa was 
diagnosed and finally 108 patients were analysed 
in this study. Subjects were randomly assigned to 
1:1 ratio to SeR 320mg+LY5mg+Se50mcg/day tre-
atment (group I) for 6 months or to control group 
(group Ic) and then underwent 24 cores prostatic re-
-biopsy with two more needle biopsies (for chronic 
inflammation evaluation) collected from the left and 
right lobes in the same previous areas allowing simi-
lar histopathological analysis.
Inclusion criteria for second group were: 
presence of LUTS due to bladder outlet obstruction 
(BOO) secondary to clinical BPH, assessed by uro-
dynamic and pressure flow evaluation, PSA > 4ng/
mL and/or DRE abnormality and/or abnormal fin-
dings on transrectal ultrasound, 12 cores prostatic 
biopsy performed for suspected prostate cancer with 
two more cores collected from the left and right 
lobes (for chronic inflammation valuation), histo-
logical diagnosis of prostatic chronic inflammation 
associated with BPH and indication for surgical 
treatment. Exclusion criteria were: treatment with 
NSAIDs or corticosteroids in the previous 6 months; 
treatment with finasteride or dutasteride, phytothe-
rapy in the previous 6 months, urinary infection, 
diagnosis of PCa. Sixty-six consecutive patients 
met inclusion criteria. Six patients dropped out for 
various reasons: 2 lost to follow-up and 4 excluded 
due to concomitant drug medication which was not 
allowed by the criteria we had established. Finally, 
a total of 60 patients were included in the analy-
sis and they were enrolled and randomly assigned 
to 1:1 ratio to SeR 320mg+LY5mg+Se50mcg/day 
and α-blockers treatment (group II) for 3 months or 
to control group (group IIc). At month 3 two-cores 
prostatic biopsy was performed in the same areas 
of the previous allowing similar histopathological 
analysis and then underwent Transurethral Resec-
tion of Prostate (TURP).
Principles outlined in the Declaration of Hel-
sinki were followed and all patients signed a written 
informed consent form.
Histopathological evaluation
Prostate specimens were fixed with 10% 
buffered formalin for 8-12 hours (biopsy), 12-24 
hours (TURP) and sent for central review by a blin-
ded pathologist.
Coloration of specimens was performed by 
hematoxylin-eosin. On the main representative area 
of each histological specimen, parameters of flogosis 
like extensions and grading of flogosis were evalua-
ted, according to the score of Nickel (17).
On paraffin sections of 5 micron were as-
sessed, by immunohistochemical technique using 
monoclonal antibodies (Dako company), B-lym-
phocytes (CD20), T-lymphocytes (CD3, CD8), and 
macrophages (CD68). The detection system was the 
universal kit LSAB of the Dako company. All the 
immunohistochemical procedures were performed 
using the automated immunostaining Optimax Plus 
system (Biogenex, San Ramon, USA).
The immunostaining specimens were asses-
sed using the Axioplan Zeiss microscope with Axio-
vision software. For each specimen with positive im-
munostaining for CD20, CD3, CD8 and CD68, only 
the main representative areas were selected, using a 
zoom 10x.
Subsequently the positive cells were coun-
ted in three fields with lens 20x, within this area, 
the medium value was considered as expression of B 
and T lymphocyte density and as expression of the 
macrophages density present in the specimen.
Statistical analysis
Baseline characteristics are presented as fre-
quencies of occurrence or mean and standard de-
viation as appropriate. Statistical differences among 
groups of frequencies were tested by Chi-square test. 
Given the not normal distribution of continuous 
data, we tested differences among independent sam-
ples by Mann-Whitney U-test.
All statistical tests were two-tailed and p-
-value < 0.05 were considered significant. Data were 
entered into Microsoft Excel for Windows (Micro-
soft Corporation, Redmond, WA). Statistical analysis 
was performed using SPSS for Windows release 17.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical results
Baseline demographic and clinical characte-
ristics of patients analyzed are listed in Table-1. No 
differences in terms of parameters collected, such 
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Table 1 - Baseline clinical and histopathological characteristics of population and comparision of groups at inclusion.
Variables PIN/ASAP patients P-value BPH patients P-value
I group 
(Profluss®)
(n=54)
Ic 
(control group)
(n = 54)
II group
(Profluss®)
(n=30)
IIc
(control group)
(n=30)
Age, y, mean ± SD 64.6 ± 4.0 65.5 ± 2.3 0.15 67.4 ± 5.7 69.8 ± 4.4 0.18
Weight, Kg, mean ± SD 74 ± 6.4 74.2 ± 5.3 0.24 75 ± 5.7 75 ± 6.55 0.43
BMI, Kg/m2, mean ± SD 26.5 ± 2.4 26.3 ± 2.1 0.35 27.1 ± 2.9 26.9 ± 1.5 0.52
Total number of infiltrates, mean ± SD 39.3 ± 4.5 38.5 ± 3.42 0.65 75.4 ± 3.4 74.4 ± 2.9 0.41
B lymphocytes (CD20), mean ± SD 14.8 ± 4.3 14.8 ± 8.8 0.84 41.5 ± 2.2 42.0 ± 1.3 0.54
T lymphocytes  (CD3), mean ± SD 6.4 ± 2.8 6.5 ± 3.2 0.76 19.5 ± 2.3 20.6 ± 4.0 0.12
T lymphocytes (CD8), mean ± SD 12.5 ± 3.7 11.5 ± 3.4 0.16 6.2 ± 3.2 6.1 ± 2.0 0.15
Macrophages (CD68), mean ± SD 5.92 ± 2.2 5.7 ± 1.3 0.54 7.1 ± 1.5 6.9 ± 2.1 0.15
Prostate volume, cc, mean ± SD 50.5 ± 19.9 52.4 ± 18.2 0.12 47.3 ± 14.8 53.4 ± 1.0 0.14
PSA, ng/mL, mean ± SD 5.5 ± 1.2 5.21 ± 2.1 0.35 5.5 ± 0.8 5.31 ± 0.9 0.65
as age, prostate volume, PSA values, urodynamic 
findings and other general health status variants 
were observed between groups.
Histopathological findings and results
At 6-month histopathological evaluation, 
a significant difference of flogosis was demonstra-
ted between Groups I and Ic, with a reduction both 
of extension (P < 0.001) and grading (P < 0.001) of 
flogosis among treated patients (Figure-1).
Histopathological evaluation performed at 
3 months in patients enrolled in Group II revealed 
no significant difference of extension and grading 
of flogosis in respect to group control IIc (Figu-
re-1). However, a slight reduction of extension and 
grading could be observed in the treated group.
A significant reduction of total interstitial 
mononuclear cells, B lymphocytes, T lymphocytes 
and macrophages in Group I compared with con-
trol group (Ic) was observed at 6-month evalua-
tion (P < 0.001) (Table-2).
Among patients with BPH (Group II), total 
interstitial mononuclear cells, B lymphocytes, T 
lymphocytes and macrophages were significan-
tly reduced at 3 month evaluation compared with 
control group (P < 0.001) (Table-3).
According with the reduction of extension 
and grade of flogosis in Group I, mean PSA va-
lues was significantly lower than in control group 
(P < 0.0001) (Table-2).
No statistical significant reduction of PSA 
value was demonstrated between Groups II and 
IIc (Table-3).
DISCUSSION
Almost all surgery-derived BPH speci-
mens show inflammatory infiltrates at histo-
logical examination (18,19); yet most of these 
patients neither have clinical signs of infection 
nor any correlation with bacterial or other fo-
reign antigens.
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Figure 1 - Extension and grading of flogosis on surgical specimens of patients treated with (Profluss®) and control 
group with PIN/ASAP (I Group) and BPH (II Group).
Table 2 - Total number of infiltrates, inflammatory cells markers included in the study and serum PSA with average findings 
in PIN/ASAP patients at 6-month evaluation.
Variables I group (Profluss®)
(n = 54)
(Mean ± SD)
Ic (Control Group)
(n = 54)
(Mean ± SD)
P-values
Total number of infiltrates 29.6 ± 4.12 38.2 ± 3.24 < 0.001
B lymphocytes (CD20) 14.20 ± 4.94 14.61 ± 4.87 < 0.001
T lymphocytes  (CD3) 6 ± 3.50 6.38 ± 2.06 < 0.001
T lymphocytes  (CD8) 5 ± 1.80 8.87 ± 4.21 < 0.001
Macrophages (CD68) 4.40 ± 1.61 5.64 ± 2.45 < 0.001
PSA, ng/mL 4.16 ± 0.89 5.62 ± 1.04 < 0.001
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In a study by Robert et al. it was found that 
most patients, treated by surgery for complicated 
and/or symptomatic BPH, had inflammatory cells 
infiltrating BPH tissues: 81% had T-lymphocytes 
markers, 52% had B-lymphocytes markers, and 
82% had macrophages markers (20). Therefore, in 
patients with high-grade prostatic inflammation 
IPSS score and prostate volume were significantly 
higher. These findings were confirmed by Mishra 
et al. (21), who compared pathology specimens 
in 374 patients who underwent transurethral re-
section of the prostate (TURP) for either LUTS or 
urinary retention. They found 70% of men with 
urinary retention have acute and/or chronic in-
flammation versus 45% of men without LUTS.
These data may support the hypothesis 
that an anti-inflammatory therapy may act to re-
lief BPH symptoms and may also condition pros-
tate tissue growth (22).
Among all phytotherapics, the lipidostero-
lic extract of Serenoa repens, a compound used 
to relief symptoms of BPH, had shown an anti-
-inflammatory activity modifying the production 
of leukotrienes and 5 hydroxyeicosatetraenoic 
acid, via the inhibition of the oxidative enzyme 
5 lypoxygenase rather than phospholipase A2 or 
cell viability. Since the infiltration of inflamma-
tory cells appears to have a role in BPH, inhibition 
of the production of chemotactic leukotrienes and 
other 5 lypoxygenase metabolites by Serenoa re-
pens could be useful in BPH treatment (23).
Serenoa Repens, in a multicenter, open pi-
lot study, was also evaluated for its effects on in-
flammatory markers. Tumor necrosis factor-α and 
IL-1b were dramatically lower in the Serenoa re-
pens-treated group; both biological markers have 
been used as indicators of prostatic inflammation 
in cases of chronic prostatitis (23).
It has been hypothesized that SeR, Ly, and 
Se, administered together, might amplify their 
therapeutic efficacy on the proliferative and in-
flammatory component of BPH (24).
The efficacy of this association was recen-
tly confirmed in an in vitro and in vivo compa-
rison study performed on rats with partial blad-
der outlet obstruction: prostate pro-inflammatory 
phenotype, as well as hyperplasia, was reduced 
more efficiently than the single compounds (25).
Analyzing specimens from patients with 
high grade PIN and/or ASAP, a statistical signi-
ficant reduction in the extension, and in the gra-
ding of the inflammatory cells infiltrate was de-
monstrated in the patients treated with SeR+Ly+Se 
(Group I).
Therefore, it was confirmed by immune-
-histochemical technique using monoclonal an-
tibodies, that mononuclear cell infiltration (B-
-lymphocytes CD20, T-lymphocytes CD3-CD8 and 
Table 3 - Total number of infiltrates, inflammatory cells markers included in the study and serum PSA with average findings 
in BPH patients at 3-month evaluation.
Variables II Group (Profluss®)
(n=30)
(Mean ± SD)
IIc (Control Group)
(n=30)
(Mean ± SD)
P-values
Total number of infiltrates 47.9 ± 2.56 71.9 ± 2.87 < 0.001
B lymphocytes (CD20) 25.8 ± 1.97 40.6 ± 1.92 < 0.001
T lymphocytes  (CD3) 12.7 ± 2.98 18.6 ± 2.31 < 0.001
T lymphocytes  (CD8) 4.1 ± 1.09 6 ± 1.17 < 0.001
Macrophages (CD68) 5.3 ± 1.05 6.7 ± 1.2 < 0.001
PSA, ng/mL 2.54 ± 0.768 2.54 ± 1.02 0.584
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macrophages CD68) is the most common pattern. 
SeR+Ly+Se combination therapy resulted in a 
statistical significant reduction of this inflamma-
tory infiltrate.
The inflammatory infiltrates are responsi-
ble for the secretion of cytokines, which are invol-
ved in the paracrine and autocrine regulation of 
stromal and epithelial cell growth. This mechanism 
has been considered to influence the development 
of prostate cancer and BPH (26): SeR+Se+Ly asso-
ciation acting on these pathway may be conside-
red to chemoprevent both conditions.
According with the reduction of extension, 
grade of flogosis and CD20, CD3, CD8,CD68, mean 
PSA values decreased from 5.62 ± 1.04 to 4.16 ± 
0.89 (p < 0.001), suggesting that PSA value could 
be an useful marker of prostate inflammation. This 
result was underlined also in a study from Li Gui-
-Zhong et al. Thus, if an elevated PSA level is con-
sidered in association with histological inflamma-
tion with detailed grading in a high number of 
biopsy specimens, it might prevent unnecessary 
repeated biopsies (27).
The aim of the analysis performed in the 
Group II was to verify whether in patients with 
bladder outlet obstruction, waiting for TURP, 
SeR+Se+LY association determined the same 
effects observed in Group I.
Comparing the results with control group, 
there were no statistically significant differences 
in terms of reducing the extension and grading of 
inflammation.
As reported in several studies, the extent 
of inflammation and grade correlated positively 
with the serum PSA level (28,29). Probably in the 
Group II we have selected patients with lower ex-
tension and grade of flogosis: this finding is also 
supported by the fact that between the two subsets 
there were no statistical significant differences in 
terms of total PSA.
Analyzing the inflammatory infiltrate, sur-
prisingly it has been documented a statistical sig-
nificant reduction of CD20, CD3, CD8, CD68. In the 
study by Vela Navarrete et al., SeR alone showed 
a reduction of the biological markers (TNFα and 
IL-1β): however, the histological findings resulted 
in a reduction only in the number of lymphocytes 
B (CD20) (23).
Possible limits of this research could be 
represented by the lack of placebo controlling. 
A multicentre and randomized, double-blinded, 
placebo-controlled study could fill this gap and 
offer results that better clarify the activity of this 
category of treatment.
CONCLUSIONS
Our data support the anti-inflammatory 
activity of the combination of SeR+Se+LY in pa-
tients with histological inflammation detected 
on biopsy specimens. Patients with bladder ou-
tlet obstruction could benefit from this therapy 
on the inflammatory component of BPH. More 
data supporting these findings may confirm the-
se evidences.
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